Prospective, Randomized, Comparative Study of Myeloablative Fludarabine/Busulfan and Fludarabine/Busulfan/Total Body Irradiation Conditioning in Myeloid Diseases

Hyung C. Suh(Science Applications International Corporation (United States)), Michèle L. Donato(The University of Texas Health Science Center at Houston), Phyllis McKiernan(Hackensack University Medical Center), Alan P Skarbnik(Novant Health), James J. De Voss(The University of Queensland), Michele Boonstra(Hackensack University Medical Center), Scott D. Rowley(Johns Hopkins Hospital), Ann Hampson(Hackensack Meridian Health), Melissa Baker(Hackensack University Medical Center), Mary E Dilorenzo(Novant Health), Bianca DeAgresta(Hackensack Meridian Health), Sukhdeep Kaur(Hackensack Meridian Health), Themba Nyirenda(Hackensack University Medical Center), D. H. Vesole, Brittany Lukasik(Hackensack University Medical Center)
Cancers
March 28, 2025
10.3390/cancers17071140
Cited by 0

Related Papers

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
|Journal of Clinical Oncology|1998|927
High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.
|PubMed|1996|645
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
|Blood|2001|516
Autologous Bone Marrow Transplantation in Patients with Acute Nonlymphocytic Leukemia, Using ex Vivo Marrow Treatment with 4-Hydroperoxycyclophosphamide
|New England Journal of Medicine|1986|441